United Therapeutics (UTHR) Competitors $391.45 -13.36 (-3.30%) Closing price 04:00 PM EasternExtended Trading$394.25 +2.80 (+0.72%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock UTHR vs. BIIB, INCY, NBIX, BMRN, EXEL, MDGL, EXAS, HALO, RGEN, and IONSShould you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Biogen (BIIB), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Repligen (RGEN), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. United Therapeutics vs. Its Competitors Biogen Incyte Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Madrigal Pharmaceuticals Exact Sciences Halozyme Therapeutics Repligen Ionis Pharmaceuticals Biogen (NASDAQ:BIIB) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations. Do analysts prefer BIIB or UTHR? Biogen presently has a consensus target price of $185.74, indicating a potential upside of 31.15%. United Therapeutics has a consensus target price of $412.69, indicating a potential upside of 5.43%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34United Therapeutics 0 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.69 Does the media prefer BIIB or UTHR? In the previous week, Biogen had 4 more articles in the media than United Therapeutics. MarketBeat recorded 42 mentions for Biogen and 38 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.30 beat Biogen's score of 1.25 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 28 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 23 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BIIB or UTHR more profitable? United Therapeutics has a net margin of 40.36% compared to Biogen's net margin of 15.31%. United Therapeutics' return on equity of 18.73% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% United Therapeutics 40.36%18.73%16.49% Which has more volatility and risk, BIIB or UTHR? Biogen has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Which has preferable valuation and earnings, BIIB or UTHR? Biogen has higher revenue and earnings than United Therapeutics. Biogen is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$10.00B2.08$1.63B$10.4613.54United Therapeutics$3.08B5.74$1.20B$25.6215.28 Do institutionals & insiders believe in BIIB or UTHR? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 10.3% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryUnited Therapeutics beats Biogen on 11 of the 16 factors compared between the two stocks. Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UTHR vs. The Competition Export to ExcelMetricUnited TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.66B$2.82B$5.75B$9.83BDividend YieldN/A48.51%6.66%4.49%P/E Ratio15.2822.6482.4426.63Price / Sales5.74725.69530.80110.54Price / Cash10.7326.3325.7028.92Price / Book2.466.7910.646.56Net Income$1.20B$32.94M$3.28B$266.04M7 Day Performance28.20%0.75%-0.08%-0.58%1 Month Performance33.02%8.36%10.36%6.24%1 Year Performance11.08%0.53%49.00%22.21% United Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UTHRUnited Therapeutics4.3866 of 5 stars$391.45-3.3%$412.69+5.4%+11.3%$17.66B$3.08B15.281,305Trending NewsAnalyst ForecastInsider TradeShort Interest ↑High Trading VolumeBIIBBiogen4.9084 of 5 stars$136.36-2.1%$185.74+36.2%-31.8%$19.99B$10.00B13.047,605Trending NewsINCYIncyte4.7077 of 5 stars$84.76-0.3%$81.60-3.7%+30.9%$16.55B$4.24B19.262,617Positive NewsShort Interest ↑NBIXNeurocrine Biosciences4.8593 of 5 stars$133.99-1.1%$159.50+19.0%+11.7%$13.29B$2.36B39.641,800News CoveragePositive NewsShort Interest ↑BMRNBioMarin Pharmaceutical4.9971 of 5 stars$58.50-0.1%$93.17+59.3%-35.2%$11.25B$3.06B17.363,040News CoveragePositive NewsAnalyst ForecastEXELExelixis4.8578 of 5 stars$37.90-1.9%$44.06+16.2%+42.8%$10.20B$2.17B18.221,147Analyst RevisionMDGLMadrigal Pharmaceuticals4.1328 of 5 stars$412.23-0.6%$445.71+8.1%+76.5%$9.15B$515.55M-32.0890Positive NewsEXASExact Sciences4.8023 of 5 stars$45.66-3.8%$67.43+47.7%-22.2%$8.64B$2.94B-8.417,000Positive NewsShort Interest ↑HALOHalozyme Therapeutics4.6479 of 5 stars$72.21+0.5%$67.11-7.1%+14.9%$8.45B$1.18B16.52390News CoveragePositive NewsInsider TradeRGENRepligen4.8268 of 5 stars$121.26-2.8%$169.45+39.7%-20.0%$6.82B$634.44M-485.021,778News CoveragePositive NewsAnalyst ForecastIONSIonis Pharmaceuticals4.2078 of 5 stars$41.82-2.0%$60.92+45.7%+20.6%$6.67B$705M-22.731,069Trending NewsAnalyst ForecastGap Up Related Companies and Tools Related Companies BIIB Alternatives INCY Alternatives NBIX Alternatives BMRN Alternatives EXEL Alternatives MDGL Alternatives EXAS Alternatives HALO Alternatives RGEN Alternatives IONS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UTHR) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UTHR Stock Alerts